Value Partners Ireland Fund ICAV –
Value Partners Health Care Fund#
-
Risk Disclosure
- Value Partners Health Care Fund (the “Fund”) primarily invests in equities and equity-related securities in healthcare companies on a worldwide basis.
- The investments of the Fund are concentrated in the health care sector which are subject to greater influences from government policies and regulations than those of other industries. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments.
- Investing in PRC market exposes the Fund to additional risks including currency repatriation risk, uncertainty of taxation policies and risk associated with Stock Connects. The Fund may also expose to RMB currency and conversion risk.
- Investing in small/mid-capitalization securities may have lower liquidity and their prices are more volatile to adverse economic developments.
- The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
- You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.
-
Performance
Performance Update
Annual Returns
Annual Returns
Performance Since Launch as at 19-11-2024
Performance Since Launch
#The funds are sub-funds of Value Partners Ireland Fund ICAV (the “Company”). The Company is both authorized and supervised by the Central Bank of Ireland (“Central Bank”) as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011. Authorization of the Company by the Central Bank shall not constitute a warranty as to the performance of the Company and the Central Bank shall not be liable or the performance or default of the Company. The authorization of the Company is not an endorsement or guarantee of the Company by the Central Bank.
Source: Value Partners & Morningstar
Performance shown is NAV to NAV in denominated currency with income reinvested and net of fees. For funds/classes denominated in foreign currencies, US/HK dollar-based investors are therefore exposed to fluctuations in the currency exchange rate. All indices are for reference only.
Investment involves risk. Past performance is not indicative of future performance. The price of units/NAV per share can go down as well as up and is not guaranteed. Investors may not get back the full amount invested. Please refer to the relevant offering documents including the risk factors.
+The Fund is one of the eligible collective investment schemes for the purpose of the New Capital Investment Entrant Scheme (New CIES) in Hong Kong with effect from 1 March 2024. -
Fund Facts
Investment Objective
The Fund aims to achieve long-term capital growth by investing primarily in equities and equity-related securities in healthcare companies including pharmaceuticals, biotechnology, healthcare services and medical technology and supplies on a worldwide basis.
Open-ended Umbrella Investment Company Value Partners Ireland Fund ICAV
Promoter and investment manager Value Partners Hong Kong Limited
Depositary HSBC Continental Europe
Legal status Authorized by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities (UCITS) pursuant to the European Communities UCITS Regulations 1
Launch date 02-04-2015
Base currency US dollar
Other currency class available AUD, AUD (hedged), CAD, CAD (hedged), Euro, Euro (hedged), GBP, GBP (hedged), HKD, NZD, NZD (hegded), RMB, RMB (hedged), SGD, SGD (hedged), USD 2
Minimum subscription AUD 10,000 / CAD 10,000 / EUR 10,000 / GBP 10,000 / HKD 80,000 / RMB 60,000/ SGD 10,000 / USD 10,000 / USD (Class Z) 10,000,000
Initial subscription fee Up to 5% of the issue price
Investment manager fees 1.5% per annum
1% per annum (for Class Z USD)
Dealing frequency Daily
Cutoff time: 11.59am Irish time- Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc) is authorized and supervised by the Central Bank of Ireland (“Central Bank”). Authorization by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. Authorization of the ICAV is not an endorsement or guarantee of the ICAV by the Central Bank.
- Transactions for currency hedging purposes may be carried out in respect of shares in the Hedged Classes; for details on this and/or for a full list of share classes, please refer to the prospectus and the relevant fund supplement.
+The Fund is one of the eligible collective investment schemes for the purpose of the New Capital Investment Entrant Scheme (New CIES) in Hong Kong with effect from 1 March 2024. -
Documents
Loading...Type of Document Date Download -
Historical Prices